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Abstract
Introduction: Wolfram syndrome (WFS) is the most frequent syndromic form of monogenic diabetes coexisting with optic atrophy and 
many other disorders. The aim of this study was to estimate the prevalence of Wolfram syndrome among children with diabetes in Poland. 
Material and methods: These calculations were performed among Polish diabetic children, aged 0–18 years, from three administrative 
regions between January 2005 and December 2011. Epidemiological data was obtained by matching the results from the EURO-WABB-
Poland Project and the PolPeDiab Registry. 
Results: Throughout the study period, we confirmed genetic diagnosis of Wolfram syndrome in 13 patients from Poland. Three patients 
originated from the studied regions with complete epidemiological data on paediatric diabetes. The total number of patients with di-
agnosed diabetes in the study equalled 2,568 cases. The prevalence of Wolfram syndrome among Polish children with diabetes is 0.12% 
(95% Confidence Interval 0.04–0.34%). 
Conclusions: We estimate that Wolfram syndrome is 26 to 35 times less frequent than monogenic diabetes (MODY and neonatal diabetes) 
in the Polish paediatric population. (Endokrynol Pol 2014; 65 (4): 295–297)
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Streszczenie 
Wstęp: Zespół Wolframa (WFS) jest najczęstszą syndromiczną formą cukrzycy monogenowej, gdzie oprócz cukrzycy występuje zanik 
nerwów wzrokowych oraz wiele innych zaburzeń. Celem pracy była ocena częstości występowania zespołu Wolframa na tle innych 
rodzajów cukrzycy w populacji pediatrycznej. 
Materiał i metody: Ocena chorobowości została przeprowadzona wśród dzieci chorych na cukrzycę, pochodzących z trzech polskich 
województw (łódzkie, pomorskie i śląskie) w wieku 0–18 lat, w okresie czasu pomiędzy styczniem 2005 roku i grudniem 2011. Dane epi-
demiologiczne uzyskano poprzez połączenie danych pochodzących z Rejestru EURO-WABB dla Polski oraz Rejestru PolPeDiab. 
Wyniki: W badanym okresie czasu potwierdzono genetycznie rozpoznanie zespołu Wolframa u 13 pacjentów na terenie Polski. Do ni-
niejszej analizy włączono 3 pacjentów z zespołem Wolframa pochodzących z badanego regionu. Całkowita liczba przypadków cukrzycy 
zdiagnozowanych w tym okresie czasu wyniosła 2568. Prewalencję zespołu Wolframa wśród pacjentów pediatrycznych z  cukrzycą 
oszacowano na 0.12% (95% Przedział Ufności 0.04–0.34%). 
Wnioski: Oceniono, że zespół Wolframa występuje w polskiej populacji pediatrycznej 26- do 35-krotnie rzadziej niż pozostałe typy 
cukrzycy monogenowej (MODY i cukrzyca noworodkowa). (Endokrynol Pol 2014; 65 (4): 295–297).
Słowa kluczowe: zespół Wolframa; cukrzyca monogenowa; cukrzyca typu 1
This study was supported by a EURO-WABB Project, Ministry of Science and Higher Education grant no. N 407 100040 and the TEAM project 
of the Foundation for Polish Science.
Introduction
Wolfram syndrome (WFS) is the most frequent 
syndromic form of monogenic diabetes coexisting 
with optic atrophy and many other disorders. This 
syndrome is a result of mutations in the wolframin 
gene (WFS1) and is inherited as an autosomal reces-
sive trait [1]. 
The aim of this study was an estimation of the preva-
lence of Wolfram syndrome among children with diabetes. 
Material and methods
An evaluation of the prevalence of Wolfram syndrome 
was performed among Polish diabetic children aged 
0–18 years between January 2005 and December 2011. 
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All patients fulfilled the clinical criteria of Wolfram 
syndrome – the coexistence of diabetes mellitus and 
optic atrophy. Diagnosis of Wolfram syndrome was 
definitely confirmed by direct sequencing of WFS1 
gene and/or MLPA (SALSA MLPA P163 GJB-WFS1 
probemix, MRC-Holland, Amsterdam, the Netherlands), 
as described previously [2]. Sequence information of 
the WFS1 gene was derived from GenBank (www.
ncbi.nlm.nih.gov). For sequencing, all exons, including 
exon-intron boundaries and 900 bp from the 5’ and 3’ 
untranslated region (UTR)/promoter region of WFS1 
were amplified by 12 primer pairs and analysed by ter-
minator cycle sequencing using Big Dye v3.0 chemistry 
on an ABI PRISM 310 capillary DNA sequencer (Applied 
Biosystems, Foster City, CA, USA) [2]. 
Epidemiological data was obtained by matching 
results from the EURO-WABB-Poland Project and 
the PolPeDiab Registry. Data of frequency of Wolfram 
syndrome was provided from the EURO-WABB-Poland 
Registry. The EURO-WABB Project started in 2011 as 
the European Union Rare Diseases Registry for Wolf-
ram-, Alstrom-, Bardet Biedl syndrome and other rare 
syndromes and deals with the recruitment and genetic 
identification of patients. The Department of Paediat-
rics, Oncology, Haematology and Diabetology, Medical 
University of Lodz is the nationwide co-ordinator of 
the EURO-WABB Project (Fig. 1). 
Diagnosis of type 1, type 2, other monogenic types of 
diabetes (MODY, neonatal diabetes), and cystic fibrosis-
related diabetes (CFRD), was performed according to 
the WHO classification. Data showing the effects of 
these efforts was reported previously [3–6].
Prevalence calculations for all analysed types 
of diabetes: type 1, type 2, other than WFS mono-
genic diabetes, and CFRD, were performed using 
the epidemiological data from the Polish PolPeDiab 
Registry. Three academic paediatric endocrinology/ 
/diabetology centres submitted complete data on the 
prevalence of diabetes in their respective regions. In 
the Slaskie and Pomorskie regions, the study centres 
(in Katowice and Gdansk) were the main reference 
departments and supervised the treatment of all chil-
dren with diabetes in those administrative districts. 
In the Lodzkie administrative region, there are two 
academic centres for paediatric diabetes care. How-
ever, the study centre was in charge of epidemiologi-
cal data collection from both regional centres and is 
responsible for the treatment of approximately 85% 
of children with diabetes in the region. Generally, 
owing to the centralised structure of diabetes care 
in the studied regions, we were able to maintain ap-
proximately 100% coverage of the three regions in 
terms of the number of children treated for diabetes 
throughout the study period. 
The study protocol was approved by the University 
Bioethics Committee at the Medical University in Lodz, 
Poland (RNN/124/11/KE and RNN/133/10/KE).
Results
In the study period, we confirmed diagnosis of 
Wolfram syndrome by genetic analysis in 13 patients 
from Poland (11 females and two males aged: 6–33, 
mean 18.7 ± 6.7 years). Three patients with Wolfram 
syndrome who originated from the three administrative 
regions (three females) aged: 6–18, mean 13.1 ± 6.3 years 
were entered into the study. Two individuals were 
homozygous for the W540X mutation and one was 
a compound heterozygote with both S167E and W648X 
mutations. All three mutations were reported earlier to 
be pathogenic [2, 7].
Epidemiological data for all analysed types of diabe-
tes: type 1, type 2, other than WFS monogenic diabetes, 
and CFRD, is summarised in Table I. The total number of 
patients with diabetes equalled 2,568 cases. Comparing 
the epidemiological data from the EURO-WABB-Poland 
Project and the PolPeDiab Registry, we found that the 
prevalence of Wolfram syndrome among paediatric pa-
tients with diabetes is 0.12% (95% Confidence Interval 
[CI] 0.04–0.34%). After combining that data with that 
from our earlier epidemiological report which showed 
the prevalence of monogenic diabetes to range from 
3.1 to 4.2% of diabetes [5], we estimated that Wolfram 
syndrome is 26 to 35 times less frequent than monogenic 
diabetes in the Polish paediatric population.
Discussion
After comparing the epidemiological data from the 
EURO-WABB-Poland Project with data from three Pol-
ish administrative regions for other types of diabetes 
in children and adolescents, we determined the preva-
Table I. Prevalence of Wolfram syndrome among a paediatric 
population with diabetes in three regions of Poland in 
2005–2011
Tabela I. Częstość występowania zespołu Wolframa na 
tle innych rodzajów cukrzycy w  populacji paediatrycznej 
w trzech regionach Polski w latach 2005–2011
Type of diabetes Number of diabetes cases 
(overall from three regions)
Wolfram syndrome 3
Other monogenic diabetes 97
Type 1 diabetes 2,425
Type 2 diabetes 25
CFRD 18
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lence of Wolfram syndrome among diabetic paediatric 
patients in Poland. We found that this value was 0.12%. 
According to some researchers, the prevalence of 
this syndrome in European population is estimated to 
be 1 in 770,000 individuals in the UK and 1 in 500,000 
in Germany [7, 8], so our findings are similar to those 
of other European countries. In other populations, the 
prevalence of Wolfram syndrome is assessed as up to 
1 in 68,000 cases in Lebanon, due to a higher frequency 
of consanguinity among parents of children with this 
syndrome [9, 10]. 
The frequency of WFS1 mutations in patients misdi-
agnosed as having the most frequent type of diabetes 
in paediatric populations — type 1 diabetes — ranges 
from about 0.57% in the UK population up to 5.5% in 
Lebanon [8, 10]. 
Other researchers have estimated that the preva-
lence of diabetes in Wolfram syndrome among patients 
with diabetes younger than 21 years in Europe is about 
1:730 [7]. In our study, the prevalence of WFS among 
children with diabetes below 18 years old was about 
1:860, which is concordant with those reports. 
In view of earlier epidemiological reports of the 
group, we were also able to show the ratios of preva-
lence between the most frequent types of monogenic 
diabetes in children with that of Wolfram syndrome, 
underlining the rarity of the latter disorder.
There are however several limitations to our study, 
intrinsic to studies on rare diseases. Wolfram syndrome 
proved to be an exceptionally rare clinical entity, and 
we were thus unable to achieve a large sample size. 
Consequently, we were unable to estimate the yearly 
incidence of Wolfram syndrome and focused on  its 
prevalence among paediatric diabetic patients instead. 
However, the aim of the study was to match two reg-
istries: EURO-WABB-Poland and PolPeDiab Registry. 
Moreover, the number of patients with Wolfram syn-
drome may have been underestimated as the natural 
history of this disease shows that the onset of diabetes 
generally precedes the development of optic atrophy 
and other disorders [11, 12]. Therefore some patients 
with Wolfram syndrome may be present within the 
dataset but are still treated as type 1 diabetes. How-
ever, as the study covered a long period of time, and 
the cohort was periodically evaluated for possible new 
cases of Wolfram syndrome, this scenario seems rather 
unlikely. 
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Figure 1. Milestones for integrative epidemiology studies among paediatric patients with diabetes in Poland
Rycina 1. Kluczowe wydarzenia integrujące w Polsce badania epidemiologiczne wśród pacjentów pediatrycznych z cukrzycą
